Protein Kinase Inhibitors: all 15,038 studies that test it
Page 81 of 151. Open to participants first (2,480), then studies with results posted, then the rest; newest registration first within each.
- FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced StageStatus unknownNCT05279677Phase 2
- Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19Status unknownNCT05279391Not applicable
- Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid TumorStatus unknownNCT05278364Phase 1/2
- Lazertinib for Patients With NSCLC Harboring Uncommon EGFR MutationsStatus unknownNCT05277701Phase 2
- Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)Status unknownNCT05277675Not applicable
- Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCTStatus unknownNCT05277454Phase 1
- Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell MalignanciesStatus unknownNCT05275504Phase 1
- A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell TumorCompletedNCT05275426Phase 2
- A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell LymphomaStatus unknownNCT05274997Phase 2
- Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT MutStatus unknownNCT05274438Phase 2
- An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid TumorsStatus unknownNCT05274191Phase 2
- A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal AdenocarcinomaCompletedNCT05273554Phase 1
- A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLLTerminatedNCT05272813Phase 1/2
- Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy SubjectsCompletedNCT05272683Phase 1
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.Active, not recruitingNCT05270044Phase 3
- A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological MalignanciesCompletedNCT05269940Phase 1/2
- A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic LeukemiaTerminatedNCT05268003Phase 2
- Multiparametric Assessment of Bone Response in mCRPC Patients Treated With CabozantinibCompletedNCT05265988Phase 2
- A Food Effect Study of KC1036 in Healthy SubjectsCompletedNCT05265338Not applicable
- A Study of KL590586 in Patients With Advanced Solid TumorsActive, not recruitingNCT05265091Phase 1/2
- Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R MutationCompletedNCT05263947Phase 2
- Optimizing Pembrolizumab Therapy With Timing and Intensification With AxitinibWithdrawnNCT05263609Phase 2
- A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCCCompletedNCT05262959Phase 2
- A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)Status unknownNCT05262413Phase 1/2
- Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)Status unknownNCT05262335Phase 2
- Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentActive, not recruitingNCT05261399Phase 3
- Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR MutationsCompletedNCT05258279Phase 2
- A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid TumorsStatus unknownNCT05258266Phase 1/2
- Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung CancerStatus unknownNCT05257512Phase 1/2
- A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast CancerActive, not recruitingNCT05257395Phase 3
- A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic CancerStatus unknownNCT05257122Phase 2
- Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsActive, not recruitingNCT05256290Phase 1/2
- Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast CancerStatus unknownNCT05255523Phase 2
- Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)Status unknownNCT05255406Phase 2
- PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.CompletedNCT05255276Phase 1
- To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedNCT05253053Phase 1/2
- Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant NeratinibActive, not recruitingNCT05252988Phase 2
- A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)Active, not recruitingNCT05252585Phase 4
- Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy SubjectsCompletedNCT05252546Phase 1
- (VELA) Study of BLU-222 in Advanced Solid TumorsTerminatedNCT05252416Phase 1
- CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast CancerActive, not recruitingNCT05251714Phase 1/2
- To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult VolunteersCompletedNCT05248074Phase 1
- Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.Status unknownNCT05246293Phase 2
- A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)Active, not recruitingNCT05245968Phase 1
- Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy ParticipantsCompletedNCT05245396Phase 1
- A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene AlterationsTerminatedNCT05242822Phase 1
- GB5121 in Adult Patients With Relapsed/Refractory CNS LymphomaTerminatedNCT05242146Phase 1
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsTerminatedNCT05241873Phase 1
- A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to TreatmentCompletedNCT05241834Phase 1
- Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCLWithdrawnNCT05239910Phase 2
- BARIcitinib Cognitive Emotional and Neural signaTuRETerminatedNCT05238896Phase 4
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
- A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200CompletedNCT05238337Phase 1
- Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney DiseaseCompletedNCT05237388Phase 2
- Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02）CompletedNCT05235100Phase 2
- Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2WithdrawnNCT05233410Phase 3
- Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal CarcinomaStatus unknownNCT05232552Phase 2
- A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune ThrombocytopeniaStatus unknownNCT05232149Phase 2
- Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.Active, not recruitingNCT05230810Phase 1/2
- YL-13027 in Patients With Advanced Solid TumorsStatus unknownNCT05228600Phase 1
- A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLCActive, not recruitingNCT05228496Phase 2
- Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast CancerWithdrawnNCT05227131Phase 2
- Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesActive, not recruitingNCT05226871Phase 2
- An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced GastrointestinalStatus unknownNCT05225844Phase 2
- A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver DysfunctionCompletedNCT05224609Phase 1
- Effect of Imatinib in Advance Liver Fibrosis PatientsStatus unknownNCT05224128Phase 1/2
- Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerCompletedNCT05223088Phase 2
- A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)Active, not recruitingNCT05222802Phase 1
- Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 AlterationsWithdrawnNCT05222165Phase 1/2
- Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsStatus unknownNCT05221775Phase 1
- Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell CarcinomaActive, not recruitingNCT05220267Phase 2
- TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver CancerStatus unknownNCT05220020Phase 3
- Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1WithdrawnNCT05219864Phase 3
- Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)Active, not recruitingNCT05218668Phase 2
- The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting ConditionsStatus unknownNCT05218616Phase 1
- A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal CancerActive, not recruitingNCT05217446Phase 2
- HL-085 in NRAS-mutated Advanced MelanomaCompletedNCT05217303Phase 2
- Fruquintinib Hepatic Impairment StudyCompletedNCT05216367Phase 1
- Fruquintinib Renal Impairment StudyCompletedNCT05216354Phase 1
- Pemigatinib in Subjects With Adenosquamous Carcinoma of the PancreasWithdrawnNCT05216120Phase 2
- A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of PatientsStatus unknownNCT05214976Phase 2
- Adavosertib and Gemcitabine in Advanced PancreaticWithdrawnNCT05212025Phase 2
- A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer PatientsStatus unknownNCT05210946Not applicable
- Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLLWithdrawnNCT05209308Phase 2
- Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLCStatus unknownNCT05209256Phase 2/3
- Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast CancerCompletedNCT05206656Phase 2
- A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.WithdrawnNCT05205252Phase 1/2
- Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell LymphomaActive, not recruitingNCT05202782Phase 2
- A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard TherapyStatus unknownNCT05202236Phase 2
- A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal CancerSuspendedNCT05200442Phase 1/2
- A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell LymphomaStatus unknownNCT05200312Phase 2
- An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143CompletedNCT05199610Phase 1
- A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerCompletedNCT05198804Phase 1/2
- 12-week Study of NFX-179 Gel in Subjects With Epidermal NeviWithdrawnNCT05195762Phase 2
- Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05195632Phase 2
- Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant PatientsActive, not recruitingNCT05193565Phase 4
- A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health VolunteersCompletedNCT05192369Phase 1
- Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPCWithdrawnNCT05191017Phase 1/2
- Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBCWithdrawnNCT05191004Phase 1/2
- HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT05190068Phase 1